-- Dr. Milligan to Remain With Company Through Year End --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 25, 2018--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.
Milligan, PhD, will step down as President and Chief Executive Officer
after a 28-year career with the company. Dr. Milligan will remain in his
current position through the end of the year, while the Board of
Directors conducts a search to identify a successor.
“It has been an honor to work at Gilead for my entire professional
career and, now that the company is on solid footing for the future, the
Board and I have agreed it is a good time to turn the reins over to a
new leader,” said Dr. Milligan. “I’m looking forward to a well-deserved
break and will then move on to new and different opportunities.”
“Today, Gilead has the right strategy in place to successfully execute
on its mission of improving the lives of people with some of the world’s
most serious diseases, led by a robust HIV franchise, an
industry-leading cell therapy platform and a late-stage pipeline in NASH
and inflammation,” commented John C. Martin, PhD, Chairman of the Board
of Directors. “Moreover, we have the resources to continue investing in
and expanding our strong R&D pipeline, which remains paramount to our
success. We are excited about our growth potential, and intend to hire a
CEO who will build on the foundation that John Milligan has put in place
and execute on our ambitious goals for the future.”
“On behalf of the entire Board, I want to thank John Milligan for his
countless contributions to Gilead over nearly 30 years, and commend him
for operating throughout his career with the highest personal and
professional integrity,” said John Cogan, PhD, Lead Independent
Director, Gilead Sciences Board of Directors. “Given his longstanding
dedication to Gilead, it is no surprise that John is committed to
facilitating a seamless transition for all of our stakeholders, as we
work to identify his successor.”
Dr. Milligan will also step down from the Gilead Board of Directors at
the end of the year. Additionally, Dr. Martin has announced his intent
to step down from the Board at the time a new CEO joins the company,
having determined that this would be a natural transition point from his
successive roles as CEO, Executive Chairman and Chairman.
The Company today also released its financial results for the second
quarter 2018. As previously announced, at 5:00 p.m. Eastern Time,
management will host a conference call to discuss financial results and
provide a general business update.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters
in Foster City, California.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018, as filed with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
For more information about Gilead at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180725005853/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792